Abbott Labs (ABT) Reports Q3 Adj-EPS of $0.92, Beats by 2c; Raises FY09 EPS Outlook
More News related to ABT
- Abbott (ABT) Seeks for ARCHITECT HE4 to be First Automated HE4 Test Available in the U.S.
- Abbott Submits New Automated Ovarian Cancer Test for U.S. Approval
- Health Discovery Corporation Partners with Major New York City Pancreatic Cancer Center to Develop a New Molecular Diagnostic Test for the Early Detection of Pancreatic Cancer
- First Global Upgrades Abbot Labs (ABT) to Long Term Outperform
- Absolute Software's Computer Lifecycle Management Solution Selected by University of Texas
More News related to Earnings
- HNI Corporation (HNI) Tops Q1 EPS by 2c; Revs Light
- Team Health (TMH) Reports Mixed Q4 Results
- Baidu (BIDU) Blows the Lid Off Q4, Shares Jump
- Aspen Insurance (AHL) Posts Q4 adj.-EPS of $1.44, Tops Views
- Acadia Realty Trust (AKR) Misses Q4 FFO by 1c; Guides Below for FY10
Abbott Laboratories (NYSE: ABT) reports Q3 EPS of $0.92, ex-items, 2 cents better than the analyst estimate of $0.90. Revenue for the quarter was $7.76 billion, which compares to the estimate of $7.76 billion.
Raises its FY09 EPS guidance from $3.65-$3.70 to $3.70-$3.72, which compares to the Street estimate of $3.69.
Related Categories
EarningsGuidance
Hot List
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
